Jaguar Health Q2 2026 revenue down 59% YoY; net loss widens to $12.7M

Jaguar Health, Inc.

2026-Q2 EPS reported -$35.11 revenue$21,497,000

Total net revenue $1.225M vs $2.979M in Q2 2025 (-59%); product revenue down 60% to $1.18M.
Net loss attributable to common stockholders $12.69M vs $10.41M; EPS -$15.68 vs -$358.94.
Sales/marketing expense fell $2.5M after Future Pak licensing Jan 12, 2026; cost of product revenue rose to ~$1.0M.
MVID NDA package expected ready end-2026; submission planned Q2 2027; crofelemer MVID data showed parenteral support reduction up to 48%.
Non-GAAP recurring EBITDA loss widened to $8.4M; loss on debt extinguishment $3.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.